What Is Melanotan II? Research on the Melanocortin Peptide

Research Disclaimer

This article reviews published scientific literature for educational purposes only. All compounds referenced are sold by Blank Peptides exclusively for in-vitro research and laboratory use. Nothing in this article constitutes medical advice, a treatment recommendation, or an endorsement of human use.

Melanotan II (MT-II) is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH), developed at the University of Arizona in the early 1990s. It activates melanocortin receptors MC1R through MC5R, a non-selective binding profile that produces simultaneous effects across pigmentation, appetite, and other melanocortin-mediated pathways.

Melanotan IICyclic HeptapeptideNon-Selective MCR Agonist

Receptor Pharmacology

MT-II binds with highest affinity to MC4R and MC1R in published binding assays. This multi-receptor profile means any research protocol must account for concurrent effects across multiple systems:

MC1R activation: drives eumelanin synthesis in melanocytes (dark pigment responsible for UV-protective tanning)
MC4R activation modulates appetite and energy homeostasis in hypothalamic neurons
MC3R/MC4R activation is implicated in sexual function pathways

Melanogenesis Research

The primary published research focus for MT-II is melanogenesis, specifically stimulating eumelanin production through MC1R activation without UV exposure.

Key published findings:

Dose-dependent increases in skin pigmentation in both animal models and human studies
Increased eumelanin density provides measurable UV attenuation
Research has explored whether peptide-induced melanogenesis can reduce UV-mediated DNA damage in skin models

Appetite and Metabolic Research

Key Insight: MC4R is a validated target in obesity research: loss-of-function MC4R mutations are the most common monogenic cause of obesity in humans. MT-II’s potent MC4R agonism produces strong anorexigenic effects in published animal studies. That same agonism is why appetite suppression appears in the side effect list below rather than as a separate finding.

This has made MT-II a useful pharmacological tool for studying melanocortin-mediated appetite control, though its non-selectivity limits utility compared to MC4R-selective compounds being developed in the pharmaceutical pipeline.

Published Safety Observations

MT-II’s non-selective binding profile means a broad side effect range in published research:

Nausea, particularly at initial exposures
Facial flushing
Appetite suppression
Cardiovascular effects linked to MC4R activation
Unpredictable pigmentation distribution, including darkening of existing nevi, which raises dermatological monitoring considerations

MT-II vs. Afamelanotide (Melanotan I)

Afamelanotide: linear α-MSH analog with greater MC1R selectivity. More targeted melanogenesis with less off-target MC4R/MC3R activation. Has regulatory approval for erythropoietic protoporphyria, giving it a formal clinical safety dataset.
Melanotan II: non-selective melanocortin agonist, which suits questions that span several melanocortin receptors at once rather than pigmentation alone.

For researchers specifically studying melanogenesis, afamelanotide offers a cleaner tool. For researchers studying broad melanocortin system pharmacology, that same non-selectivity is the reason to reach for it.

Browse These Compounds

Melanotan II